Showing 1 - 5 results of 5 for search 'Huseyin Naci', query time: 0.03s
Refine Results
-
1
Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway by Mahnum Shahzad, Huseyin Naci, Katharine M. Esselen, Joseph A. Dottino, Anita K. Wagner
Published 2024Connect to this object online.
Book -
2
-
3
Efficacy and safety of interim oncology treatments introduced for solid cancers during the COVID-19 pandemic in England: a retrospective evidence-based analysisResearch in context by Mark P. Lythgoe, Alica-Joana Emhardt, Huseyin Naci, Jonathan Krell, Richard Sullivan, Ajay Aggarwal
Published 2024Connect to this object online.
Book -
4
Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020Research in context by Yuxuan Wei, Yichen Zhang, Ziyue Xu, Guoan Wang, Yue Zhou, Huangqianyu Li, Luwen Shi, Huseyin Naci, Anita K. Wagner, Xiaodong Guan
Published 2024Connect to this object online.
Book -
5
Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysisResearch in context by Adriana M. Ivama-Brummell, Fernanda L. Marciniuk, Anita K. Wagner, Claudia G.S. Osorio-, Sabine Vogler, Elias Mossialos, Carla L. Tavares-, Huseyin Naci
Published 2023Connect to this object online.
Book